hematological malignancies with DIC showing decreasing fibrinogen (100mg/dl)
Conditions
Interventions
Thrombomodulin alfa is given as 380U/Kg of 30 minute div. Treatment duration is decided by the physicians. Observation duration is from the time of administration of thrombomodulin alfa to the time o
Sponsors
Saitama Medical Center, Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) the hematological malignancy patients with fibrinogen less than 100mg/dl, compatible with DIC criteria of old the Ministry of Health & Welfare. But, the hematological malignancy patients with fibrinogen more than 100mg/dl are not restricted if the physicians require the administration of thrombomodulin alfa. 2) The agreed patients or families with their own decisions under the sufficient explanation by the physicians.
Exclusion criteria
Exclusion criteria: 1) the patients with severe bleeding such as brain, lung, and digestive tract 2) the patients with history of anaphylaxis to the contents in thrombomodulin alfa 3) 4) the inappropriate patients decided by the physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time-dependent change regarding DIC score, clinical manifestation, data of coagulation, PDMP, and HMGB1 | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical outcome, total dose of transfusion (RCC, platelet, and FFP), adverse events during observation duration | — |
Countries
Japan
Contacts
Public ContactMichihide Tokuhira
Saitama Medical Center, Saitama Medical University Department of hematology
Outcome results
None listed